MaaT Pharma Receives Negative CHMP Trend for MaaT013 in aGvHD
Lyon, France, May 20, 2026 MaaT Pharma announced that the Committee for Medicinal Products for Human Use (CHMP) of...
AI drug discovery artificial intelligence ASCO 2026 Autoimmune Disease Bio-Pharma biologics biopharma Biopharmaceuticals Biotechnology Cancer Immunotherapy Cancer Research cancer therapy Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development FDA fda approval FDA clearance Gene Therapy Healthcare Innovation healthcare technology Immuno-Oncology immunology Immunotherapy Medical Devices MedTech Monoclonal Antibody Neurology Oncology oncology innovation Orphan Drug Phase 1 trial Phase 2 Trial Phase 3 trial Precision Medicine Precision Oncology rare disease rare diseases Regenerative Medicine regulatory compliance targeted therapy
Lyon, France, May 20, 2026 MaaT Pharma announced that the Committee for Medicinal Products for Human Use (CHMP) of...
MISSISSAUGA, Ontario — December 15, 2025 — Novo Nordisk Canada Inc. announced that Health Canada has granted conditional marketing...
